The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.